EVNIN LUKE sold $66K of HOWL (indirect holdings)

EVNIN LUKE sold 141,106 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at an average of $0.47 ($0.45–$0.48) across 3 trades over 2026-05-27 to 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · EVNIN LUKE
Published May 29, 2026, 10:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$HOWL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

Low
01

Why it matters

The insider sale is modest in dollar terms and unlikely to move the stock significantly.

02

Market read

Routine insider transaction with limited market impact.

03

What to watch

Potential future dilution or financing needs

Relevance 2/10Novelty 2/10Timing: post-market filing

Background

SEC Form 4 filing discloses director EVNIN LUKE selling 141,106 shares of Werewolf Therapeutics (HOWL) for $66,200 via a 10b5‑1 plan.

Market effects

minimal impact on biotech sector

none

none

Counterpoint

Sale may signal insider concern despite small size

Key entities

  • Werewolf Therapeutics, Inc.

    Biotech firm listed under ticker HOWL (non‑US listed).

  • EVNIN LUKE

    Director of Werewolf Therapeutics executing a pre‑arranged sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HOWLMedAI 8/10

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial , WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the ou